The GLP-1 Guide

GLP-1 receptor agonists are the most consequential metabolic drugs in a generation. This guide is for anyone who has been prescribed one, is considering it, or wants to understand the science behind the headlines. By the end you’ll know what these medications do in the body, what the strongest human trials found, and how to weigh the real trade-offs honestly.

What GLP-1 does in the body

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. It does several things at once:

• Slows stomach emptying, so food stays with you longer
• Signals the brain to reduce appetite and food intake
• Stimulates insulin and suppresses glucagon, improving blood-sugar control

The natural hormone breaks down within minutes. GLP-1 medications are engineered to resist that breakdown, turning a brief post-meal signal into a steady, days-long one. Semaglutide targets the GLP-1 receptor alone. Tirzepatide is a dual agonist: it activates both the GLP-1 and GIP receptors (GIP is another incretin hormone), which appears to add to its effect.

What the trials show

The human evidence here is unusually strong, and it comes from large, placebo-controlled randomized trials rather than marketing.

Weight loss

In the STEP 1 trial (NEJM, 2021), 1,961 adults with overweight or obesity but without diabetes were randomized to weekly semaglutide 2.4 mg or placebo alongside lifestyle support for 68 weeks. The semaglutide group lost an average of 14.9% of body weight, versus 2.4% on placebo. About 86% reached at least 5% loss, and half reached 15% or more.

Tirzepatide went further. In SURMOUNT-1 (NEJM, 2022), 2,539 adults were randomized across three doses and placebo for 72 weeks. Average weight loss reached 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, compared with 3.1% on placebo. (These are the treatment-regimen estimand figures, the intention-to-treat result regardless of adherence, the same basis as the STEP 1 numbers above; the trial’s on-treatment “efficacy” figures run a couple of points higher.)

These are the largest average weight reductions ever produced by a drug therapy, approaching what some bariatric procedures achieve, in a weekly injection.

Cardiovascular benefit

The SELECT trial (NEJM, 2023) tested whether the benefit extends beyond the scale. It enrolled 17,604 adults with established cardiovascular disease and overweight or obesity, but without diabetes, and followed them for about 3.3 years. Semaglutide reduced major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, or non-fatal stroke) by 20% (hazard ratio 0.80; event rate 6.5% vs 8.0% on placebo). This was the first outcome trial to show a GLP-1 drug prevents cardiovascular events in people without diabetes.

Trial	Drug	Duration	Key result
STEP 1	Semaglutide 2.4 mg	68 weeks	-14.9% body weight
SURMOUNT-1	Tirzepatide 5-15 mg	72 weeks	-15.0% to -20.9% body weight
SELECT	Semaglutide 2.4 mg	~3.3 years	20% fewer major cardiac events

The trade-offs

No honest guide skips these.

1. Side effects. Nausea and other gastrointestinal symptoms are common, especially during dose escalation. In SELECT, adverse events led 16.6% of the semaglutide group to stop, versus 8.2% on placebo, a real, if usually manageable, rate.
2. Muscle loss. Rapid weight loss includes lean mass alongside fat. Resistance training and adequate protein matter for protecting it.
3. Durability. These treat an ongoing condition rather than curing it. Stopping usually leads to substantial regain, which is why clinicians increasingly frame them as long-term tools.
4. Cost and access. Real-world barriers shape who benefits. Without insurance coverage these medications can run hundreds of dollars a month, and supply shortages have periodically limited availability, practical constraints that determine outcomes as much as the biology does.

How to think about it

GLP-1 therapy is a genuine advance and a tool with real costs. The evidence for weight loss and, in higher-risk patients, cardiovascular protection is about as solid as clinical evidence gets. What the trials can’t tell you is how the drug fits your life, your history, and your goals: that’s a conversation with your prescriber.

The people who do best treat it as one part of a system (training, protein, sleep), not a replacement for it. Nothing here is medical advice.

The takeaway

GLP-1 medications reliably produce large weight loss, improve metabolic markers, and, in people with existing heart disease, reduce cardiovascular events. They also carry side effects, cost, muscle-loss risk, and a strong tendency toward regain when stopped. Understood as a long-term management tool rather than a quick fix, they are one of the most important advances in metabolic medicine, used deliberately, with eyes open.

Browse the latest GLP-1 and metabolic research, or explore the Learn hub for the broader picture.